JP2015521201A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521201A5 JP2015521201A5 JP2015515140A JP2015515140A JP2015521201A5 JP 2015521201 A5 JP2015521201 A5 JP 2015521201A5 JP 2015515140 A JP2015515140 A JP 2015515140A JP 2015515140 A JP2015515140 A JP 2015515140A JP 2015521201 A5 JP2015521201 A5 JP 2015521201A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxylamine
- triazin
- propylamino
- bis
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 4,6-bis-n-propylamino- [1,3,5] triazin-2-yl Chemical group 0.000 claims description 110
- 239000000203 mixture Substances 0.000 claims description 93
- 150000003839 salts Chemical class 0.000 claims description 52
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 51
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 36
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 33
- YLCKQUGICAAQPH-UHFFFAOYSA-N 2,6-bis(propylamino)-1h-1,3,5-triazin-4-one Chemical compound CCCNC1=NC(O)=NC(NCCC)=N1 YLCKQUGICAAQPH-UHFFFAOYSA-N 0.000 claims description 31
- FJNLCHNQVJVCPY-UHFFFAOYSA-N 2-n-methoxy-2-n-methyl-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)OC)=N1 FJNLCHNQVJVCPY-UHFFFAOYSA-N 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 28
- 125000003342 alkenyl group Chemical group 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 23
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 22
- 238000001228 spectrum Methods 0.000 claims description 22
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 21
- 241000124008 Mammalia Species 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 18
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 18
- 125000004898 2,2-dimethylpropylamino group Chemical group CC(CN*)(C)C 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 12
- 125000003107 substituted aryl group Chemical group 0.000 claims description 12
- 229910019142 PO4 Inorganic materials 0.000 claims description 11
- 239000010452 phosphate Substances 0.000 claims description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- REUOZJCPYNCRBF-UHFFFAOYSA-N 4-(2,2-dimethylhydrazinyl)-7-methyl-n-propylpyrrolo[2,3-d]pyrimidin-2-amine Chemical compound CCCNC1=NC(NN(C)C)=C2C=CN(C)C2=N1 REUOZJCPYNCRBF-UHFFFAOYSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 8
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000004892 2-methylpropylamino group Chemical group CC(CN*)C 0.000 claims description 6
- PRJNUFMLJGTTLK-UHFFFAOYSA-N 2-n-ethoxy-2-n-methyl-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)OCC)=N1 PRJNUFMLJGTTLK-UHFFFAOYSA-N 0.000 claims description 6
- RDILYRIEKAIVCM-UHFFFAOYSA-N 2-n-ethyl-2-n-phenylmethoxy-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(CC)OCC=2C=CC=CC=2)=N1 RDILYRIEKAIVCM-UHFFFAOYSA-N 0.000 claims description 6
- SEGYWYKVHKZJGM-UHFFFAOYSA-N 2-n-ethyl-2-n-propan-2-yloxy-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(CC)OC(C)C)=N1 SEGYWYKVHKZJGM-UHFFFAOYSA-N 0.000 claims description 6
- SYLVJUORWRFJRX-UHFFFAOYSA-N 2-n-methoxy-2-n,4-n,6-n-trimethyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(NC)=NC(N(C)OC)=N1 SYLVJUORWRFJRX-UHFFFAOYSA-N 0.000 claims description 6
- SKERTMQMVAHYAA-UHFFFAOYSA-N 2-n-methoxy-2-n-methyl-4-n-propyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(N)=NC(N(C)OC)=N1 SKERTMQMVAHYAA-UHFFFAOYSA-N 0.000 claims description 6
- FCMDIOJBKPDJTF-UHFFFAOYSA-N 2-n-methyl-2-n-(2-methylpropoxy)-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)OCC(C)C)=N1 FCMDIOJBKPDJTF-UHFFFAOYSA-N 0.000 claims description 6
- ROLMXTKKKRBDJB-UHFFFAOYSA-N 4-n,6-n-diethyl-2-n-methoxy-2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCNC1=NC(NCC)=NC(N(C)OC)=N1 ROLMXTKKKRBDJB-UHFFFAOYSA-N 0.000 claims description 6
- WJTYZSFQHDUIMO-UHFFFAOYSA-N 6-(2,2-dimethylhydrazinyl)-2-n,4-n-dipropyl-1,3,5-triazine-2,4-diamine Chemical compound CCCNC1=NC(NCCC)=NC(NN(C)C)=N1 WJTYZSFQHDUIMO-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- UOXANTZAXQUAJS-UHFFFAOYSA-N n-[4-[methoxy(methyl)amino]-6-(propylamino)-1,3,5-triazin-2-yl]propanamide Chemical compound CCCNC1=NC(NC(=O)CC)=NC(N(C)OC)=N1 UOXANTZAXQUAJS-UHFFFAOYSA-N 0.000 claims description 6
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 6
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 6
- BAHUYEGLKLVQMH-UHFFFAOYSA-N 2-n-(cyclopropylmethoxy)-2-n-methyl-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)OCC2CC2)=N1 BAHUYEGLKLVQMH-UHFFFAOYSA-N 0.000 claims description 5
- IAEDKSVIELLHKM-UHFFFAOYSA-N 2-n-methyl-2-n-propan-2-yloxy-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)OC(C)C)=N1 IAEDKSVIELLHKM-UHFFFAOYSA-N 0.000 claims description 5
- PVPZKMBWMQVTRP-UHFFFAOYSA-N 6-(oxazinan-2-yl)-2-n,4-n-dipropyl-1,3,5-triazine-2,4-diamine Chemical compound CCCNC1=NC(NCCC)=NC(N2OCCCC2)=N1 PVPZKMBWMQVTRP-UHFFFAOYSA-N 0.000 claims description 5
- 108091006146 Channels Proteins 0.000 claims description 4
- 102000016469 Large-Conductance Calcium-Activated Potassium Channels Human genes 0.000 claims description 4
- 108010092555 Large-Conductance Calcium-Activated Potassium Channels Proteins 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000036470 plasma concentration Effects 0.000 claims description 3
- 101001049835 Homo sapiens Potassium channel subfamily K member 3 Proteins 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 102100023207 Potassium channel subfamily K member 3 Human genes 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 claims description 2
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 claims 3
- HFBZWHLZONCMAC-UHFFFAOYSA-N 2-n-methyl-4-n,6-n-dipropyl-2-n-(thiophen-2-ylmethoxy)-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)OCC=2SC=CC=2)=N1 HFBZWHLZONCMAC-UHFFFAOYSA-N 0.000 claims 3
- QKYDUNIUDGDKFH-UHFFFAOYSA-N 2-n-phenylmethoxy-2-n-propan-2-yl-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(OCC=2C=CC=CC=2)C(C)C)=N1 QKYDUNIUDGDKFH-UHFFFAOYSA-N 0.000 claims 3
- HQEGVXOTHWEJLF-UHFFFAOYSA-N 6-[methyl(methylamino)amino]-2-n,4-n-dipropyl-1,3,5-triazine-2,4-diamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)NC)=N1 HQEGVXOTHWEJLF-UHFFFAOYSA-N 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 35
- 230000000241 respiratory effect Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 0 C*(*1)N(C)c2*1c(N(*)**)nc(N*)n2 Chemical compound C*(*1)N(C)c2*1c(N(*)**)nc(N*)n2 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 4
- 206010038678 Respiratory depression Diseases 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- NDCBURZPAWXYJR-UHFFFAOYSA-N n-[4,6-bis(propylamino)-1,3,5-triazin-2-yl]hydroxylamine Chemical compound CCCNC1=NC(NO)=NC(NCCC)=N1 NDCBURZPAWXYJR-UHFFFAOYSA-N 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- JXEGHKNWISAGCP-UHFFFAOYSA-N 2-n-(2,2-difluoroethoxy)-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(NOCC(F)F)=N1 JXEGHKNWISAGCP-UHFFFAOYSA-N 0.000 description 3
- GWZQEKFZSNRQKQ-UHFFFAOYSA-N 2-n-methoxy-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(NOC)=N1 GWZQEKFZSNRQKQ-UHFFFAOYSA-N 0.000 description 3
- BGQPOIOPRRRXFA-UHFFFAOYSA-N 2-n-methyl-2-n-phenylmethoxy-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)OCC=2C=CC=CC=2)=N1 BGQPOIOPRRRXFA-UHFFFAOYSA-N 0.000 description 3
- YDMNMZIIXFTGIQ-UHFFFAOYSA-N 2-n-prop-2-enoxy-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(NOCC=C)=N1 YDMNMZIIXFTGIQ-UHFFFAOYSA-N 0.000 description 3
- NLEATKVIPXDZSS-UHFFFAOYSA-N N-[[4,6-bis(propylamino)-1,3,5-triazin-2-yl]oxy]-N-propan-2-ylhydroxylamine Chemical compound C(CC)NC1=NC(=NC(=N1)NCCC)ON(O)C(C)C NLEATKVIPXDZSS-UHFFFAOYSA-N 0.000 description 3
- FGNLEIGUMSBZQP-UHFFFAOYSA-N cadaverine dihydrochloride Chemical compound Cl.Cl.NCCCCCN FGNLEIGUMSBZQP-UHFFFAOYSA-N 0.000 description 3
- UWDCNOSFAPNLCH-UHFFFAOYSA-N n-[4,6-bis(propylamino)-1,3,5-triazin-2-yl]-n-methylhydroxylamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)O)=N1 UWDCNOSFAPNLCH-UHFFFAOYSA-N 0.000 description 3
- ZTBBOZNOVYWNKI-UHFFFAOYSA-N n-[4,6-bis(propylamino)-1,3,5-triazin-2-yl]-n-propan-2-ylhydroxylamine Chemical compound CCCNC1=NC(NCCC)=NC(N(O)C(C)C)=N1 ZTBBOZNOVYWNKI-UHFFFAOYSA-N 0.000 description 3
- OKXVUNQSYSZVQF-UHFFFAOYSA-N n-methoxy-n-methyl-5,8,11-trioxa-2,14,16,18,19-pentazabicyclo[13.3.1]nonadeca-1(19),15,17-trien-17-amine Chemical compound N1CCOCCOCCOCCNC2=NC(N(C)OC)=NC1=N2 OKXVUNQSYSZVQF-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- VVFNKRFSOQCQJP-DDDPLHQBSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-1,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C[C@@H]2[C@@]3(C)C(C)CC(=O)C=C3CC[C@H]2[C@@H]2CC[C@H](C(C)=O)[C@]21C VVFNKRFSOQCQJP-DDDPLHQBSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020591 Hypercapnia Diseases 0.000 description 2
- 206010021133 Hypoventilation Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 208000004166 Obesity Hypoventilation Syndrome Diseases 0.000 description 2
- 206010035004 Pickwickian syndrome Diseases 0.000 description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
- 229960000571 acetazolamide Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 208000008784 apnea Diseases 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229930003827 cannabinoid Natural products 0.000 description 2
- 239000003557 cannabinoid Substances 0.000 description 2
- 229940065144 cannabinoids Drugs 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- OFAPSLLQSSHRSQ-UHFFFAOYSA-N 1H-triazine-2,4-diamine Chemical compound NN1NC=CC(N)=N1 OFAPSLLQSSHRSQ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/482,837 US20120295911A1 (en) | 2010-11-29 | 2012-05-29 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases |
| US13/482,837 | 2012-05-29 | ||
| PCT/US2013/043052 WO2013181217A2 (en) | 2012-05-29 | 2013-05-29 | Novel compounds and compositions for treatment of breathing control disorders or diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015521201A JP2015521201A (ja) | 2015-07-27 |
| JP2015521201A5 true JP2015521201A5 (enExample) | 2016-07-14 |
Family
ID=49674035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515140A Pending JP2015521201A (ja) | 2012-05-29 | 2013-05-29 | 呼吸制御障害または呼吸制御疾患の処置用の新規化合物および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2855438A4 (enExample) |
| JP (1) | JP2015521201A (enExample) |
| KR (1) | KR20150020616A (enExample) |
| CN (1) | CN104602694A (enExample) |
| AU (1) | AU2013267570A1 (enExample) |
| BR (1) | BR112014029703A2 (enExample) |
| CA (1) | CA2875012A1 (enExample) |
| HK (1) | HK1209118A1 (enExample) |
| SG (1) | SG11201407964YA (enExample) |
| WO (1) | WO2013181217A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104926816A (zh) * | 2014-03-19 | 2015-09-23 | 江苏先声药物研究有限公司 | 一种托法替布类似物及其制备方法与应用 |
| FR3076751B1 (fr) * | 2018-01-18 | 2020-10-23 | Lebronze Alloys | Electrode de soudage pour toles en aluminium ou acier et procede d'obtention de l'electrode |
| WO2022235771A1 (en) * | 2021-05-04 | 2022-11-10 | Enalare Therapeutics Inc. | Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof |
| KR20240167901A (ko) * | 2022-04-01 | 2024-11-28 | 에날레어 테라퓨틱스 인크. | 호흡 자극제 비강 제형 |
| EP4543455A4 (en) * | 2022-06-24 | 2026-06-03 | Enalare Therapeutics Inc | METHODS OF TREATMENT FOR NEUROLOGICAL VENTILATORY FAILURE |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4269832A (en) * | 1978-04-12 | 1981-05-26 | American Cyanamid Company | Method of treating arthritic disease |
| DE3401675A1 (de) * | 1984-01-19 | 1985-07-25 | Bayer Ag, 5090 Leverkusen | Neue polyamine und ein verfahren zu ihrer herstellung |
| US5661148A (en) * | 1989-09-19 | 1997-08-26 | Teijin Limited | Pyrrolo[2,3-d]pyrimidine derivatives, process for producing the same and pharmaceutical preparation comprising the same as active ingredient |
| US7169785B2 (en) * | 2001-09-21 | 2007-01-30 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
| CN101885707B (zh) * | 2009-05-15 | 2012-08-29 | 中国科学院化学研究所 | 三嗪类衍生物及其制备方法与作为杀虫剂的用途 |
| SG10201601507YA (en) * | 2010-11-29 | 2016-04-28 | Galleon Pharmaceuticals Inc | Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases |
| US20120295911A1 (en) * | 2010-11-29 | 2012-11-22 | Galleon Pharmaceuticals, Inc. | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases |
| BR112015011213A2 (pt) * | 2012-11-15 | 2017-08-29 | Galleon Pharmaceuticals Inc | Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição. |
-
2013
- 2013-05-29 HK HK15109840.6A patent/HK1209118A1/xx unknown
- 2013-05-29 EP EP13798039.7A patent/EP2855438A4/en not_active Withdrawn
- 2013-05-29 CA CA2875012A patent/CA2875012A1/en not_active Abandoned
- 2013-05-29 SG SG11201407964YA patent/SG11201407964YA/en unknown
- 2013-05-29 WO PCT/US2013/043052 patent/WO2013181217A2/en not_active Ceased
- 2013-05-29 KR KR20147036621A patent/KR20150020616A/ko not_active Withdrawn
- 2013-05-29 JP JP2015515140A patent/JP2015521201A/ja active Pending
- 2013-05-29 AU AU2013267570A patent/AU2013267570A1/en not_active Abandoned
- 2013-05-29 CN CN201380040132.0A patent/CN104602694A/zh active Pending
- 2013-05-29 BR BR112014029703A patent/BR112014029703A2/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013544285A5 (enExample) | ||
| USRE49556E1 (en) | Compounds and compositions as protein kinase inhibitors | |
| EP2582432B1 (en) | Ureido-pyrazole derivatives for use in the treatment of rhinovirus infections | |
| AU2016331955B2 (en) | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors | |
| ES2779748T3 (es) | Compuestos para el tratamiento de infecciones víricas por paramixovirus | |
| ES2377947T3 (es) | Compuestos de pirimidina como inhibidores de la interleucina 12 (IL-12) | |
| JP2024523839A5 (enExample) | ||
| RU2014124953A (ru) | Производные аминопиридина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2) | |
| US20110288081A1 (en) | Pyrimidine compounds and uses thereof | |
| WO2017125506A1 (en) | Aryl substituted pyrimidines for use in influenza virus infection | |
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| IL305388A (en) | History of 4,2-diaminoquinazoline and their medical uses | |
| JP2013518887A (ja) | Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン | |
| MX2023009961A (es) | Compuestos heterociclicos antivirales. | |
| MX2024012335A (es) | Compuestos heterociclicos antivirales | |
| CA2769300A1 (en) | Methods and compositions for treating leukemia | |
| RU2021132080A (ru) | Селективный ингибитор киназы JAK1 | |
| NZ754085A (en) | Pyrrolopyrimidines as cftr potentiators | |
| NZ754085B2 (en) | Pyrrolopyrimidines as cftr potentiators |